DOCSLIB.ORG

___Flanders, the Northern Dutch-Speaking Region of Belgium

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
___Flanders, the Northern Dutch-Speaking Region of Belgium GLOBAL TRADE More than beer and chocolates Flanders, the northern Dutch-speaking region of Belgium, has a lot to offer South African companies that want to enter the European market. ince the Middle Ages, Flanders was a textile founders, Prof Mantagu and Dr Jeff Schell, were the first region, making tapestries and clothing. The to develop plants resistant to insects, pests and herbicides textile sector diversified into flooring products by genetically engineering the plants. Many of the corn, from carpets to wooden flooring, technical textiles cotton, yellow maize and soybeans currently available in and artificial grass. Flanders is now expanding in South Africa are GM (genetically modified) crops. Snew areas of expertise such as smart textiles and new Medical biotechnology (red biotech) has developed materials, where for example, microchips are integrated rapidly in Flanders, mostly at the five universities and in the textile fabrics. In the golden Sixties Flanders four academic hospitals for clinical trials. More than 140 was successful in attracting multinational chemical companies have been formed over the years. ___ __ companies to the port of Antwerp. The port is an ideal In the ICT space, Flanders is one of the worldwide pio- Luc Fabry gateway to the international markets and the European neers in nanotechnology (chip technology) thanks to the Trade and Investment hinterland. The different plants are interconnected InterUniversity Micro Electronics Center (IMEC), linked to Commissioner, with pipelines and connected with other ports (such as the oldest university of Europe: KU Leuven. IMEC expand- Flanders Investment Zeebrugge and Amsterdam) making it a very efficient ed its expertise in nanotechnology and chip technology & Trade production location. Sasol of South Africa is present in to application domains such as healthcare, smart cities, Flanders with a distribution facility in Antwerp. mobility and manufacturing, logistics and energy. Another wave of investments in the Sixties came from Flanders is now on the forefront of high-tech research and the automotive sector. Today Volvo (XC40 model) and the digital economy. More than 120 companies have spun Audi (E-Tron model) in the Brussels region have flexible off since IMEC was established in 1986. production plants. Flanders also attracts automotive The food-processing sector is well-established: the suppliers as well as truck and coach/bus manufacturers. beverage sector boasts 224 breweries, 1 000 types Volvo trucks has the largest manufacturing plant in Ghent. of beers and the largest brewing company, ABInbev. New investments also stem from the pharmaceutical Chocolate production is the highest in Europe, but the sector. The pharmaceutical development started in region also excels in the production of frozen vegetables, 1953 with Dr Paul Janssen, who founded Janssen fries and bakery products. Pharmaceuticals in Beerse. His challenge was to merge Flanders is strategically located in pharmacology and chemistry knowledge: 80 medicines the middle of Europe, making it an ideal were discovered in different fields, including Opiod location for a European distribution Center (Fentanyl – pain medication), Mikonazole (Daktarin (EDC). More than 250 companies (including – antifungal medication) and Loperamide (Imodium – Nike, Bose, Black & Decker, Volvo, Mazda, diarrhea medication) to name a few. Scania, Ikea, Ingram Micro, Greenspan and Green biotech was introduced to Flanders by the Chiquita) selected Flanders as an EDC. company PGS (Plant Genetic Systems) in 1992. The South African companies should consider Flanders as an R&D location or distribution hub for a variety of sectors. Flanders excels ___ __ in developing the “Triple Helix’’ (company: education: IMEC has 2 clean government). Building your presence in Europe reduces rooms and is at your dependence on the rand, your company becomes the forefront of part of the various ecosystems and you can tap into chip design and the qualified personnel and a broad range of incentives. digital economy www.flandersinvestmentandtrade.com 16 | www.opportunityonline.co.za.
Load more

Recommended publications
  • Special Edition Inside
    A Publication by The American Society for the Pharmacology and Experimental Therapeutics Pharmacologist Inside: Feature articles from 2014-2015 Special Edition VISIT THE ASPET CAREER CENTER TODAY! WWW.ASPET.ORG/CAREERCENTER/ 4 5 12 21 30 41 WHAT YOU NEED: ASPET’S CAREER CENTER HAS IT 52 Jobseekers: Employers: No registration fee Searchable résumé database Advanced search options Hassle-free posting; online account management tools 61 Sign up for automatic email notifi cations of new jobs that Reach ASPET’s Twitter followers (over 1,000), match your criteria LinkedIn Members (over 2,000), and email subscribers (over 4,000) Free & confi dential résumé posting 71 Post to just ASPET or to entire NHCN network Access to jobs posted on the National Healthcare Career Network (NHCN) Sign up for automatic email notifications of new résumés that match your criteria Career management resources including career tips, coaching, résumé writing, online profi le development, Job activity tracking and much more ASPET is committed to your success: The ASPET Career Center is the best resource for matching job seekers and employers in the pharmacology and related health science fi elds. Our vast range of resources and tools will help you look for jobs, fi nd great employees, and proactively manage 9650 Rockville Pike, Bethesda, MD 20814-3995 your career goals. Main Office: 301.634.7060 www.aspet.org ASPET Career Center Full Page Ad 2015 Updated.indd 1 1/15/2016 3:18:16 PM The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics. THE PHARMACOLOGIST VISIT THE ASPET CAREER CENTER TODAY! PRODUCTION TEAM Rich Dodenhoff Catherine Fry, PhD WWW.ASPET.ORG/CAREERCENTER/ Judith A.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • Chinese Terracotta Warriors
    28 How Paul Janssen’s Drugs Saved the CCHHIINNEESSEE TTEERRRRAACCOOTTTTAA WWAARRRRIIOORRSS Rebecca J. Anderson The Chinese Terracotta Army, dating from approximately the late third century BCE, was discovered on March 29, 1974 to the east of Xi’an in Shaanxi Province, China. Photo: Shutterstock The Pharmacologist • March 2015 29 Chinese museum officials gazed with dismay at their Janssen label (3). These included repackaging and priceless army of ancient statues. For 22 centuries, the distributing generic penicillin and sulfonamides, which terracotta warriors had been protected and preserved in the were increasingly in demand after the war. Paul’s mother, soil of China’s Yellow River valley (1). Now, less than 20 Margriet Fleerakers, served as office manager and also years after these old soldiers emerged from their supervised the production line, including quality control (3). subterranean fortress, many of them had become infected Paul finished high school in 1943. To avoid forced and were suffering from a mysterious rash (2). Local labor in the German factories, he secretly enrolled in archeologists suspected the warriors’ moldy rash was due to college (at the age of 16) with the help of his uncle, Emiel fungi, but they lacked specialized laboratory equipment and Janssen (3). The 12 Jesuit teachers at the Faculté Notre- had only limited expertise to diagnose and treat the ailment. Dame de la Paix in Namur, Belgium, offered intensive The detective who stepped forward to solve this courses in physics, biology, philosophy, and chemistry to a mystery and thwart an archeological catastrophe was an handful of students, including Paul, without the knowledge unlikely hero: a businessman, physician, and scientist who of the German occupiers (2, 3).
    [Show full text]
  • Book Review Paul Janssen
    BOOK REVIEW PAUL JANSSEN: PIONEER IN PHARMA & IN CHINA By Geerdt Magiels, Dundee: Dundee University Press, 2008, 258 pp. (incl. appendices and bibliography), £15.00, ISBN 978-1-84586-53-0 The history of Janssen Pharmaceutica and its evolvement in China is central to this homage to Paul Janssen, who set up the company in 1953; led it through a merger with Johnson & Johnson in 1961; built up relations with China from the 1960s onwards; and left clear footprints on its research agenda and company management style. The book owes its existence to Paul Janssen, who commissioned it to the author Geerdt Magiels. However, Janssen died shortly after their first meeting in 2003. The book aims to make known the scientific, business and human achievements of Paul Janssen. As such, there are scatterings of descriptions of major events in Janssen’s life; group photographs of important occasions and celebrations; and advice and adages on how to collaborate (for example, to have an open mind; to be creative; to allow local people to run the business; to work through friendship and compromise; to have patience; and to show mutual respect). The book gives corporate meaning to a global audience of the role of large pharmaceutical companies in developing countries. A role that involves the efforts made by such companies to advertise themselves as a bridge between rich and poor; their motivation by concerns for global health; and contributors to the well-being and development of people in developing countries. As a eulogy, this book can hardly be expected to meet academic standards.
    [Show full text]
  • PDF Version of This Page
    About this Report Annual overview 2013 Janssen Global Public Health founded Launch of INVOKANA® (canagliflozin), IMBRUVICA™ (ibrutinib), OLYSIO™ (simeprevir) Dr. Paul Stoffels in top 25 of the biopharmaceutical sector Janssen-Cilag adjusts organization in Belgium and the Netherlands Janssen wins Supply Chain Award 2013 Join forces in the fight against brain diseases Economic trade mission in India Open doors for the first time in many years 10 years the difference for people with HIV Animal rights activists protest Dr. Koen Andries celebrated First Lifetime Achievement Award FIT Start-up of combined heat and power plant House of Work Ability European Medical Information Framework (EMIF) Pillcoach Labyrinth Psychotica HepCoach Janssen Global Public Health founded In 2013 Janssen announced the creation of Janssen Global Public Health (GPH), a major step in the organization’s commitment to finding solutions, together with others, which may turn the tide of global healthcare and offer an answer to the medical needs of, among others, the most vulnerable regions. The new structure joins all efforts made by Janssen in the field of development and availability of innovative medicines. Our goal is to address seemingly intractable health challenges in new and unexpected ways. Janssen GPH mainly focuses on diseases which are a heavy burden for countries with limited resources and emerging markets. Launch of INVOKANA® (canagliflozin), IMBRUVICA™ (ibrutinib), OLYSIO™ (simeprevir) In 2013 three new products were launched in the United States and several other In addition, the FDA approved IMBRUVICA™ (ibrutinib) capsules for patients with countries. In March 2013 Janssen announced the approval by the US Food and mantle cell lymphoma (MCL).
    [Show full text]
  • English- Drug Design with Dr. Paul Janssen- 26 10 11
    Drug Design with Dr. Paul Janssen Narrated by Paul Lewi, former collaborator of Dr. Paul Janssen 1 In this monograph I would like to tell about the research and the personality of Dr. Paul Janssen, the founder of Janssen Pharmaceutica. Like several of my former colleagues, I have worked for more than forty years with Dr. Paul Janssen or Dr. Paul, as he was always called by his collaborators with much respect and affection. Our first research building was rather small. It comprised a laboratory for chemistry and pharmacology. There wasn’t much more. After five decades the company has expanded to become a large village with more than four thousand people. Fig.1 The Janssen laboratory in Beerse at the start in 1957 and more recently. 2 When I first met Dr. Paul he had just finished medical school. Forty years later Paul Janssen had become the most productive drug inventor of all time. 1955 Fig.2 Dr. Paul in the early days of the laboratory and at the peak of his research activities. You may have the impression 1from the two photographs that Dr. Paul talked often about fishing. It looks as if in the beginning he wanted to catch a very big fish. A very important medicine, of course. For many years his fishing went very well, although a few fishes were a little bit smaller than he had hoped. Nevertheless he built the most famous medicinal research laboratory of the world. 3 Success came rapidly from the start. Many people then visited us. But the visitors did not understand where our success came from.
    [Show full text]
  • Revisiting the Vincentian Family Tree
    Vincentian Heritage Journal Volume 27 Issue 2 Article 4 Spring 3-1-2008 Revisiting The Vincentian Family Tree Betty Ann McNeil D.C. Follow this and additional works at: https://via.library.depaul.edu/vhj Recommended Citation McNeil, Betty Ann D.C. (2008) "Revisiting The Vincentian Family Tree," Vincentian Heritage Journal: Vol. 27 : Iss. 2 , Article 4. Available at: https://via.library.depaul.edu/vhj/vol27/iss2/4 This Articles is brought to you for free and open access by the Vincentian Journals and Publications at Via Sapientiae. It has been accepted for inclusion in Vincentian Heritage Journal by an authorized editor of Via Sapientiae. For more information, please contact [email protected]. 61 Revisiting The Vincentian Family Tree B BETTY ANN MCNEIL, D.C. Introduction The Vincentian Family is illustrative of the cycle of created life—birth and death, change and growth, like the author of Ecclesiastes reminds us that "there is an appointed time for everything, and a time for every affair under the heaven."' In many ways the spread of the charism of Vincent de Paul (1581-1660) and Louise de Marillac (1591-1660) through their spiritual progeny exemplifies the mysterious way God "has put the timeless into their hearts, without persons ever discovering, from beginning to end, the work which God has done."' One way of facilitating an ongoing discovery process about the work God has done (and continues to do) is to take a new look at the genesis and growth of the charism of Saint Vincent and Saint Louise, and how their spirit has been incarnated through institutional expressions around the globe, particularly religious institutes in the Vincentian tradition.
    [Show full text]
  • AN ORAL HISTORY of NEUROPSYCHOPHARMACOLOGY the FIRST FIFTY YEARS Peer Interviews
    AN ORAL HISTORY OF NEUROPSYCHOPHARMACOLOGY THE FIRST FIFTY YEARS Peer Interviews Volume Two: Neurophysiology Copyright © 2011 ACNP Thomas A. Ban (series editor) AN ORAL HISTORY OF NEUROPSYCHOPHARMACOLOGY Max Fink (volume editor) VOLUME 2: Neurophysiology All rights reserved. No part of this book may be used or reproduced in any manner without written permission from the American College of Neuropsychopharmacology (ACNP). Library of Congress Cataloging-in-Publication Data Thomas A. Ban, Max Fink (eds): An Oral History of Neuropsychopharmacology: The First Fifty Years, Peer Interviews Includes bibliographical references and index ISBN: 1461161452 ISBN-13: 9781461161455 1. Electroencephalography and neurophysiology 2. Pharmaco-EEG 3. Sleep EEG 4. Cerebral blood flow 5. Brain metabolism 6. Brain imaging Publisher: ACNP ACNP Executive Office 5034A Thoroughbred Lane Brentwood, Tennessee 37027 U.S.A. Email: [email protected] Website: www.acnp.org Cover design by Jessie Blackwell; JBlackwell Design www.jblackwelldesign.com AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY AN ORAL HISTORY OF NEUROPSYCHOPHARMACOLOGY THE FIRST FIFTY YEARS Peer Interviews Edited by Thomas A. Ban Co-editors Volume 1: Starting Up - Edward Shorter Volume 2: Neurophysiology - Max Fink Volume 3: Neuropharmacology - Fridolin Sulser Volume 4: Psychopharmacology - Jerome Levine Volume 5: Neuropsychopharmacology - Samuel Gershon Volume 6: Addiction - Herbert D. Kleber Volume 7: Special Areas - Barry Blackwell Volume 8: Diverse Topics - Carl Salzman Volume 9: Update - Barry Blackwell Volume 10: History of the ACNP - Martin M. Katz VOLUME 2 NEUROPHYSIOLOGY ACNP 2011 VOLUME 2 Max Fink NEUROPHYSIOLOGY Preface Thomas A. Ban Dedicated to the Memory of Jonathan O. Cole, President ACNP, 1966 PREFACE Thomas A. Ban In Volume 1 of this series, 22 clinicians and basic scientists reflected on their contributions to the “starting up” of neuropsychopharmacology (NPP).
    [Show full text]
  • Sustainability Report 2010
    Sustainability Report 2010 Janssen Pharmaceutica NV Foreword The pharmaceutical sector in 2010 was again con- The above information is also clearly reflected in our fronted with very significant cuts in the budgets set annual figures. The turnover increased by 196 million aside for medication, both at home and abroad. euro compared to 2009, while the other operating TThese cuts were mainly a consequence of the eco- income increased by 95 million euro in 2010. Profit nomic crisis and the credit problems in a number of amounted to 22 million euro, which is 26 million euro countries during 2008 and 2009, and they also have more than in 2009. The investment figures for both an impact on Janssen. The price reductions imposed the campus in Beerse and the campus in Geel de- in the past years, and the taxation on prescription monstrate that we still firmly believe in Belgium as medicine turnover continue to negatively impact our our place of business. In 2010, we spent more than 1 profitability. billion euro on Research & Development, in addition to substantial sums on infrastructure and new tech- Despite the loss in income due to the expiry of major nologies. In Beerse, for example, major investments patents in recent years, Janssen has continued to were made in a production line for the production of invest in Research & Development, and this has McNeil products and in the necessary adjustments to resulted in even more pressure on the company’s the building in order to prepare it for the move of our profitability. The pharmaceutical industry is currently sister company Tibotec-Virco’s employees from characterized by a decline in the efficiency and pro- Mechelen to Beerse.
    [Show full text]
  • Paul A.J. Janssen
    Paul A.J. Janssen Turnhout, Belgio, 12/9/1926 – Roma, 11/11/2003 Titolo Professore di Farmacologia e Presidente, Janssen Research Foundation, Beerse, Belgio Nomina 25/6/1990 Principali premi, riconoscimenti e accademie St.-Jozefscollege, Turnhout (Belgium): humanities (1937-1943); Facultés Notre-Dame de la Paix, Namur (Belgium): Bachelor of Natural Sciences (magna cum laude) (1943-1945); Catholic University of Louvain and State University of Ghent (Belgium): Doctor of Medicine (magna cum laude) (1945-1951); Part-time assistant: State University of Ghent, to Prof. C. Heymans (1950-1956); University of Cologne (Germany), to Prof. Dr. J. Schuller (1951-1952); research in the family business, N.V. Produkten Richter (Belgium) (1953-1957); President and Director of research, Janssen Pharmaceutica NV. (1958-1991); Vice Chairman, Johnson & Johnson International, New Brunswick, NJ (USA) (1979-1991); Chairman, Janssen Research Foundation Worldwide, Beerse (Belgium) (1987-2003); Honorary Chairman of the Board of Directors of Janssen Pharmaceutica NV. (1991-2003). He held over 100 patents as inventor of several drugs; authored or co-authored more than 832 scientific publications; received 20 honorary doctorates: Antwerpen, Gent, Leuven and Liège (Belgium), Edmonton, Halifax and Montreal (Canada), Prague (Czech Republic), Nanjing (China), Düsseldorf and Frankfurt (Germany), Szeged (Hungary), Dublin (Ireland), Beersheba (Israel), Pavia and Rome (Italy), Maastricht (Netherlands), Granada (Spain), Lund (Sweden) and Istanbul (Turkey); was a member/ director
    [Show full text]
  • Annual Report
    2012 ANNUAL REPORT “It is difficult, but if you are convinced, you can do it!” Ethiopian researcher Alemtsehay Tsegay INSIDE THIS ANNUAL REPORT: ‘We want to be heard!’ 6 Giving a voice to Bolivian street children and their mothers The impact of over a decade of university cooperation between Flanders and Ethiopia ‘The change has come 18 from the inside.’ ALEMTSEHAY TSEGAY BRUNO NEUVILLE 2 Ethiopian resaercher leads 26 The oral history of project on crop productivity Batho township in the National Museum in MARTIN VALCKE Bloemfontein 10 Universities in Ecuador and Flanders unite on biodiversity PAUL JANSSEN 28 International BRAM GOvaeRTS recognition for 14 Billionaires seek out Flemisch university cooperation agricultural engineer for development trailblazer RUDY GevaeRT KOEN DE FEYTER 22 ICT projects in Cuba and A30 new future for VLIR-UOS Ethiopia: When Google cannot provide the answer KOEN DE FEYTER 34 VLIR-UOS chair in UNIVERSITIC turbulent times 24 Minister Labille presents ICT prize in DR Congo BUDGET 36 VLIR-UOS 2012 SEP VERBOOM and top 10 countries 25 Ecodesign award for travel grant recipient Cover picture: Luc Janssens de Bisthoven, Ethiopia THIS IS NOT AID, It’s global INNOVATION! evelopment cooperation is coming Development cooperation at VLIR-UOS under fire. Politicians are increasingly invests in people who create, share and apply Dpointing up the adverse effects it can knowledge. They look for answers to social chal- have. It’s said that development cooperation lenges together. We invest in strong partners to removes any incentive to work together in the find strong solutions. South, and first and foremost eases our own Is that perhaps the other form of cooperation consciences.
    [Show full text]
  • Español- El Diseño De Fármacos Con El Dr. Paul Janssen
    El Diseño de Fármacos con el Dr. Paul Janssen Narrado por Paul Lewi, ex colaborador del Dr. Paul Janssen 1 A lo largo de esta monografía, voy a hablar sobre el trabajo de investigación y la personalidad del Dr. Paul Janssen, fundador de Janssen Pharmaceutica. Yo trabajé más de cuarenta años con el Dr. Paul Janssen, o simplemente el Dr. Paul, como siempre le han llamado sus colaboradores con mucho respecto y afecto. Cuando le conocí, el Dr. Paul acababa de terminar sus estudios de medicina. Cuarenta años más tarde, Paul Janssen se había convertido en el creador de fármacos más prolífico de todos los tiempos. 19 1955 1989 1989 Fig.1 El Dr. Paul Janssen. Por las dos fotos pueden imaginarse que el Dr. Paul hablaba muy a menudo de la “pesca”. Al principio, era como si quisiera pescar un pez muy grande. Un 2 medicamento muy importante. Y durante años, la pesca se le dio muy bien, aunque algunos ejemplares no hayan sido tan grandes como esperaba. En todo caso, el Dr. Paul creó el laboratorio de investigación farmacológica más prestigioso del mundo. Nuestro primer centro de investigación era bastante pequeño. Sólo tenía un laboratorio de química y farmacología. No había mucho más. No obstante, en cincuenta años la empresa ha crecido mucho y hoy es una amplia comunidad en la que trabajan más de tres mil personas. 1957 1957 2004 2004 Fig.2 Janssen Pharmceutica en Beerse . El éxito nos llegó enseguida, desde el principio. Mucha gente nos visitaba, como ustedes ahora, pero no entendían cómo podían salir tan bien las cosas.
    [Show full text]